Subject to Re-evolution
Among medical devices with a manufacturing (import) license or notification, devices for which the Commissioner of the Ministry of Food and Drug Safety (MFDS) determines that safety and effectiveness should be reassessed.
Quality Assurance
Since it is impossible to obtain all the information on the safety and efficacy of newly developed medical devices and rare medical devices with only limited data at the time of approval, the aim is to efficiently manage the safety and efficacy by investigating and confirming factors affecting them for a wide range of patients after approval and then reflecting them in the approval matters.
Medical Device Act
Enforcement Rule of Medical Device Act
Re-evolution Regulation of Medical Device
Among medical devices with a manufacturing (import) license or notification, devices for which the Commissioner of the Ministry of Food and Drug Safety (MFDS) determines that safety and effectiveness should be reassessed.
STEP 01
Selection and notice of Re-evolution subjects
From 1 to 3 years before the Re-evolution application date
STEP 02
Determination and public notice of Re-evolution products
STEP 03
Re-evolution application
Within the Re-evolution application period
STEP 04
Conduct of Re-evolution and draft preparation
STEP 05
Public inspection
One month from the date of public notice
STEP 06
Submission of comments
STEP 07
Finalization and public notice of Re-evolution results
According to the schedule announced by the MFDS after review
STEP 08
Follow-up measures
Within 1–2 months from the date of public notice
Because not all safety and effectiveness information for innovative or rare medical devices can be obtained from limited data at the time of approval, factors affecting safety and effectiveness are investigated and verified in a broad patient population after approval and reflected in the approved labeling to enable efficient management.
Medical Devices Act
Enforcement Rules of the Medical Devices Act
Regulations on Post-Market Surveillance of Medical Devices
Products classified as innovative or rare medical devices for which the Commissioner of the MFDS determines that post-market surveillance of safety and effectiveness is necessary.